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Introduction
Inhibition of the multidrug efflux transporter P-glycopro-
tein (P-gp) at the blood-brain barrier (BBB) is considered
a promising strategy in order to increase intracerebral pen-
etration of therapeutics, such as antiepileptic and antican-
cer drugs. The aim of this study was to evaluate the
usefulness of (R)-[11C]verapamil (VPM) and small-ani-
mal positron emission tomography (μPET) to measure P-
gp inhibition at the BBB following administration of the
third-generation P-gp inhibitor tariquidar (TQD, Xenova,
UK).
Methods
Five Wistar Unilever rats underwent paired VPM μPET
scans, one baseline scan followed by i.v. administration of
TQD (15 mg/kg) and a second PET scan at 2 hour after
TQD administration. Arterial blood sampling was per-
formed along with analysis of metabolism and plasma
protein binding of VPM.
Results
Following TQD administration, the brain-to-plasma ratio
of radioactivity was increased by a factor of 11–16 as com-
pared to baseline scans, whereas VPM metabolism and
plasma protein binding were left unaffected.
Conclusion
Our pilot data suggest that VPM PET is a sensitive tool to
quantitatively visualize P-gp inhibition at the animal and
human BBB.
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